Drug intelligence / Profile preview

haloperidol + methylphenidate

Development stage
Unknown
Lead developer
Janssen Pharmaceutica
Modality
Small Molecules
Administration
Oral, Intramuscular, Intravenous, Transdermal
01

Overview

Haloperidol + methylphenidate is a combination of two pharmaceutical drugs, each with distinct mechanisms of action. Haloperidol is a first-generation (typical) antipsychotic that primarily acts as an antagonist at dopamine D2 receptors in the brain, reducing dopaminergic neurotransmission and thereby treating symptoms of psychosis, agitation, and certain behavioral disorders[4][6]. Methylphenidate is a central nervous system stimulant that functions mainly as a norepinephrine–dopamine reuptake inhibitor (NDRI), increasing synaptic concentrations of these neurotransmitters to improve attention and reduce hyperactivity and impulsivity[7][8]. This combination has been studied in children with hyperactivity or aggressive behavior to assess cognitive effects; results suggest small improvements in performance with methylphenidate and low-dose haloperidol[1]. The concurrent use may be considered in complex neuropsychiatric cases but requires careful monitoring due to potential pharmacological interactions.

02

Targets

SIGMAR1 (Sigma non-opioid intracellular receptor 1)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on haloperidol + methylphenidate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on haloperidol + methylphenidate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call